Logo image of BRM.DE

BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Price, Quote, News and Overview

FRA:BRM - Deutsche Boerse Ag - US1101221083 - Common Stock - Currency: EUR

57.3  +2.37 (+4.31%)

BRM.DE Quote, Performance and Key Statistics

BRISTOL-MYERS SQUIBB CO

FRA:BRM (3/7/2025, 7:00:00 PM)

57.3

+2.37 (+4.31%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High58.79
52 Week Low36.42
Market Cap116.28B
Shares2.03B
Float2.02B
Yearly Dividend2.22
Dividend Yield4.12%
PE54.57
Fwd PE9.12
Earnings (Next)04-24 2025-04-24/bmo
IPO07-05 1929-07-05


BRM.DE short term performance overview.The bars show the price performance of BRM.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15 20 25

BRM.DE long term performance overview.The bars show the price performance of BRM.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 -5 10 -10 15

The current stock price of BRM.DE is 57.3 EUR. In the past month the price increased by 4.68%. In the past year, price increased by 16.82%.

BRISTOL-MYERS SQUIBB CO / BRM Daily stock chart

BRM.DE Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
1LLY.MI ELI LILLY & CO 67 760.43B
LLY.DE ELI LILLY & CO 66.98 760.15B
ZEG.DE ASTRAZENECA PLC 21.82 446.45B
JNJ.DE JOHNSON & JOHNSON 16.81 372.31B
1JNJ.MI JOHNSON & JOHNSON 16.61 367.98B
NOV.DE NOVO NORDISK A/S-B 26.21 355.97B
SNW.DE SANOFI 14.32 275.64B
SAN.PA SANOFI 14.27 274.84B
1SAN.MI SANOFI 14.19 273.18B
6MK.DE MERCK & CO. INC. 12.64 224.82B
1MRKX.MI MERCK & CO. INC. 12.47 221.79B
PFE.DE PFIZER INC 8.69 140.81B

About BRM.DE

Company Profile

BRM logo image Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The firm's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

Company Info

BRISTOL-MYERS SQUIBB CO

Route 206 And Province Line Road

Princeton NEW JERSEY US

Employees: 34100

Company Website: https://www.bms.com/

Investor Relations: https://www.bms.com/investors.html

Phone: 16092524621

BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ

What is the stock price of BRISTOL-MYERS SQUIBB CO today?

The current stock price of BRM.DE is 57.3 EUR. The price increased by 4.31% in the last trading session.


What is the ticker symbol for BRISTOL-MYERS SQUIBB CO stock?

The exchange symbol of BRISTOL-MYERS SQUIBB CO is BRM and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is BRM.DE stock listed?

BRM.DE stock is listed on the Deutsche Boerse Ag exchange.


What is the price forecast or stock price prediction for BRISTOL-MYERS SQUIBB CO stock?

31 analysts have analysed BRM.DE and the average price target is 57.6 EUR. This implies a price increase of 0.52% is expected in the next year compared to the current price of 57.3. Check the BRISTOL-MYERS SQUIBB CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BRISTOL-MYERS SQUIBB CO worth?

BRISTOL-MYERS SQUIBB CO (BRM.DE) has a market capitalization of 116.28B EUR. This makes BRM.DE a Large Cap stock.


How many employees does BRISTOL-MYERS SQUIBB CO have?

BRISTOL-MYERS SQUIBB CO (BRM.DE) currently has 34100 employees.


What are the support and resistance levels for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?

BRISTOL-MYERS SQUIBB CO (BRM.DE) has a support level at 56.97 and a resistance level at 57.31. Check the full technical report for a detailed analysis of BRM.DE support and resistance levels.


Is BRISTOL-MYERS SQUIBB CO (BRM.DE) expected to grow?

The Revenue of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to decline by -4.64% in the next year. Check the estimates tab for more information on the BRM.DE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BRISTOL-MYERS SQUIBB CO (BRM.DE) stock pay dividends?

BRISTOL-MYERS SQUIBB CO (BRM.DE) has a dividend yield of 4.12%. The yearly dividend amount is currently 2.22. Check the full fundamental report for a detailed analysis of BRM.DE dividend history, reliability and sustainability.


When does BRISTOL-MYERS SQUIBB CO (BRM.DE) report earnings?

BRISTOL-MYERS SQUIBB CO (BRM.DE) will report earnings on 2025-04-24, before the market open.


What is the Price/Earnings (PE) ratio of BRISTOL-MYERS SQUIBB CO (BRM.DE)?

The PE ratio for BRISTOL-MYERS SQUIBB CO (BRM.DE) is 54.57. This is based on the reported non-GAAP earnings per share of 1.05 and the current share price of 57.3 EUR. Check the full fundamental report for a full analysis of the valuation metrics for BRM.DE.


BRM.DE Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to BRM.DE. When comparing the yearly performance of all stocks, BRM.DE is one of the better performing stocks in the market, outperforming 76.39% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

BRM.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to BRM.DE. BRM.DE has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BRM.DE Financial Highlights

Over the last trailing twelve months BRM.DE reported a non-GAAP Earnings per Share(EPS) of 1.05. The EPS decreased by -84.8% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -9.66%
ROE -54.78%
Debt/Equity 2.93
Chartmill High Growth Momentum
EPS Q2Q%-1.76%
Sales Q2Q%7.54%
EPS 1Y (TTM)-84.8%
Revenue 1Y (TTM)7.32%

BRM.DE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 68% to BRM.DE. The Buy consensus is the average rating of analysts ratings from 31 analysts.

For the next year, analysts expect an EPS growth of 498.05% and a revenue growth -4.64% for BRM.DE


Ownership
Inst Owners80.77%
Ins Owners0.07%
Short Float %N/A
Short RatioN/A
Analysts
Analysts68.39
Price Target57.6 (0.52%)
EPS Next Y498.05%
Revenue Next Year-4.64%